louisiana semaglutide nausea lawsuit class action Professor Ana Santos Rutschman weighed in on recent lawsuits alleging popular Once praised as a breakthrough
Description
The medication is administered as a once-weekly subcutaneous injection, with dosing gradually increased over several weeks to minimize gastrointestinal side effects
Results failed to show the benefit of GLP-1 receptor agonists in reducing the risk of heart failure
Melnik BC, Plewig G
J Clin Endocrinol Metab 2024;109(3):e1267-e1279
